The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

A spokesperson for Danish drugmaker Novo Nordisk said earlier this month that the company also remained committed to is DEI programme. GSK on Thursday also proposed increasing the annual salary of ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

GSK (GSK) plc announces the commencement of its share buyback program, as announced in its 2024 full year results announcement published on 5 February 2025. The Program will return an additional ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow refreshing and invigorating. After all, that oh-so familiar routine of phone calls, online ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...